June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory...

Mon, Jun 3

"On June 4, the FDAs Psychopharmacologic Drugs Advisory Committee is holding a meeting to discuss Lykos Therapeutics’ new drug application for #MDMA-assisted therapy as a treatment for PTSD. The #FDA says they expect to make a decision in mid-August." https://t.co/BmcPiqTdqU

197

The Committee will discuss new drug application (NDA) 215455, for midomafetamine (MDMA), submitted by Lykos Therapeutics, for the proposed indication of trea...

Discover